SilcsBio competes in the rapidly growing $6 billion/year bioinformatics industry. Bioinformatics can be seen as a series of individual tools (known as services) that assist at each stage of drug discovery and development. These services are generally packaged together using a Service-Oriented Architecture. The SOA enables the inputs and outputs of each service to communicate. Because it is of little value to use one service without a few or many of the others, the companies that control the SOAs have a dominant control on the market channels. At the heart of the problem with the services involved in drug lead discovery is their inaccurate representation of lead-protein interactions. SilcsBio’s first product directly addresses the failures of other algorithms to properly model drug candidate-protein interactions. Thus, the company’s entrylevel market opportunity is to displace the service that currently maps protein surfaces with SilcsBio’s technology.